IDEAYA Biosciences, Inc. IDYA
32.26 USD -0.46 (-1.39%)
Nov 12, 2026, 11:06 AM EST
31.45 Day range 32.51
26.81 52-week range 42.68
- YTD
- -6.68%
- 1 year
- +0.97%
News
benzinga.com Mizuho Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $39 Mizuho analyst Graig Suvannavejh maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and lowers the price target from $44 to $39.
benzinga.com Citigroup Maintains Buy on IDEAYA Biosciences, Raises Price Target to $66 Citigroup analyst Yigal Nochomovitz maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and raises the price target from $65 to $66.- benzinga.com RBC Capital Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $45 RBC Capital analyst Leonid Timashev maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and lowers the price target from $48 to $45.
benzinga.com Truist Securities Reiterates Buy on IDEAYA Biosciences, Lowers Price Target to $57 Truist Securities analyst Gregory Renza reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and lowers the price target from $59 to $57.
benzinga.com Guggenheim Maintains Buy on IDEAYA Biosciences, Lowers Price Target to $52 Guggenheim analyst Paul Jeng maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and lowers the price target from $57 to $52.
benzinga.com Wedbush Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $63 Wedbush analyst Robert Driscoll maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and raises the price target from $60 to $63.- benzinga.com IDEAYA Biosciences Q3 EPS $(1.22) Misses $(1.18) Estimate, Sales $10.242M Beat $6.857M Estimate IDEAYA Biosciences (NASDAQ:IDYA) reported quarterly losses of $(1.22) per share which missed the analyst consensus estimate of $(1.18) by 4.27 percent. This is a 191.73 percent decrease over earnings…
benzinga.com IDEAYA to Present Updated Melanoma Drug Data at Upcoming ESMO Congress IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a leading precision medicine oncology company, today announced updated clinical data from three ongoing studies evaluating darovasertib in metastatic and…- benzinga.com William Blair Initiates Coverage On IDEAYA Biosciences with Outperform Rating William Blair analyst Alethia Young initiates coverage on IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform rating.
- benzinga.com Guggenheim Maintains Buy on IDEAYA Biosciences, Raises Price Target to $57 Guggenheim analyst Paul Jeng maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and raises the price target from $54 to $57.
- benzinga.com IDEAYA Biosciences Announced First Patient Has Been Dosed In The OptimUM-11 Phase 3 Registrational Trial Evaluating Darovasertib In Combination With Crizotinib For Patients With Primary Uveal Melanoma Global Phase 3 registrational trial evaluating darovasertib, a first-in-class oral protein kinase C (PKC) inhibitor, in combination with crizotinib, an oral cMET inhibitor, as adjuvant therapy for…
- benzinga.com Citizens Reiterates Market Outperform on IDEAYA Biosciences, Maintains $42 Price Target Citizens analyst Silvan Turkcan reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Market Outperform and maintains $42 price target.
- benzinga.com IDEAYA Sets November R&D Day To Share New Pancreatic Cancer Research And Strategy IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced its upcoming Investor R&D Day in…
benzinga.com IDEAYA Reaches FDA Agreement On Late-Stage Trial Plan For Lung Cancer Drug, Plans Phase 3 Lung Cancer Study For IDE849 By Year-End 2026 IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced a successful FDA Type C meeting to…- benzinga.com IDEAYA Biosciences Enters Clinical Collaboration With Roche's Genentech To Evaluate The Efficacy And Safety Of IDE892, Its Investigational MTA-Cooperative PRMT5 Inhibitor, In Combination With GDC-7035, Genentech's KRAS G12D Inhibitor, In Patients With Pancreatic Ductal Adenocarcinoma Collaboration to to evaluate the efficacy and safety of IDE892, its investigational, potential best-in-class MTA-cooperative PRMT5 inhibitor, in combination with GDC-7035 (RG6620), Genentech's KRAS…
benzinga.com Truist Securities Maintains Buy on IDEAYA Biosciences, Lowers Price Target to $59 Truist Securities analyst Gregory Renza maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and lowers the price target from $63 to $59.- benzinga.com Wedbush Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $60 Wedbush analyst Robert Driscoll maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and raises the price target from $58 to $60.
benzinga.com IDEAYA Biosciences Q2 EPS $(1.22) Misses $(1.09) Estimate, Sales $8.857M Beat $5.015M Estimate IDEAYA Biosciences (NASDAQ:IDYA) reported quarterly losses of $(1.22) per share which missed the analyst consensus estimate of $(1.09) by 11.93 percent. This is a 38.64 percent decrease over losses…- benzinga.com Ideaya Biosciences Initiated Part 2 Monotherapy Expansion In Its Phase 1/2 Trial Of IDE892 In Mtap-Deleted Solid Tumors, With A Focus On Non-small Cell Lung Cancer And Pancreatic Ductal Adenocarcinoma IDE892 is a potential best-in-class PRMT5 inhibitor with 1,400-fold selective MTA-PRMT5 cooperative binding vs SAM-PRMT5 cooperative binding, and CYP3A4 IC50 greater than 45 micromolar with no…
- benzinga.com IDEAYA Biosciences Announces Presentations At 2026 European Society of Medical Oncology Meeting October 23-27, Providing Updates Across IDEAYA's Clinical Pipeline IDEAYA Presentations:2092P (Poster Presentation); Neoadjuvant Darovasertib in Primary Uveal Melanoma: Follow-Up Data from the Phase 2 OptimUM-09 Study. Presenting Author - Mark Shackleton, MBBS, PhD,…
- benzinga.com RBC Capital Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $48 RBC Capital analyst Leonid Timashev maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and lowers the price target from $53 to $48.
- benzinga.com Truist Securities Maintains Buy on IDEAYA Biosciences, Lowers Price Target to $63 Truist Securities analyst Gregory Renza maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and lowers the price target from $65 to $63.
benzinga.com Ideaya Biosciences Enrolls First Patient In Its Phase 1 Trial Of IDE892 In Combination With IDE397 In Mtap-deleted Pancreatic And Lung Cancers IDE892 is a potential best-in-class MTA-Cooperative PRMT5 combination partner with MAT2A and pan-RAS inhibitors, with favorable drug-like propertiesIDE892 has a CYP3A4 IC50 greater than 45…- benzinga.com Wedbush Reiterates Outperform on IDEAYA Biosciences, Maintains $58 Price Target Wedbush analyst Robert Driscoll reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and maintains $58 price target.
benzinga.com Mission Produce Posts Downbeat Q2 Earnings, Joins Ideaya Biosciences, Perrigo And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session U.S. stock futures higher, Nasdaq up 200 points. Mission Produce (NASDAQ: AVO) shares down on weak earnings. Other stocks also down in pre-market.
benzinga.com Why Nuvalent Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket GSK to acquire Nuvalent for $10.6 billion, shares rise 38.2%. Other gainers include CCTG, CHAI, RGNT, MTEN, NCRA, ZTG, EPSM, DBI, APLD. Losers include BYAH, NOTV.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session - benzinga.com IDEAYA Biosciences Plans To Commence $300M Common Stock Offering IDEAYA Biosciences, Inc. (NASDAQ:IDYA) today announced that it intends to offer and sell up to $300.0 million of shares of its common stock and, in lieu of common stock, to offer and sell to certain…
- benzinga.com IDEAYA Enters Collaboration With Roche To Evaluate The Efficacy And Safety Of IDE892, Its Investigational PRMT5 Inhibitor, With Roche's RG6505 IDEAYA entered into a clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1…
- benzinga.com Wedbush Reiterates Outperform on IDEAYA Biosciences, Maintains $58 Price Target Wedbush analyst Robert Driscoll reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and maintains $58 price target.
- benzinga.com IDEAYA Biosciences And Servier Presented Complete Data From Primary Analysis Of Phase 2/3 OptimUM-02 Trial For Negative Metastatic Uveal Melanoma At ASCO Annual Meeting Key Findings from OptimUM-02Primary endpoint (Phase 2 portion): progression free survival by BICRThe trial met the primary endpoint, with patients treated with the darovasertib combination…
- benzinga.com Mizuho Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $50 Mizuho analyst Graig Suvannavejh maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and lowers the price target from $52 to $50.
benzinga.com Earnings Scheduled For May 5, 2026 - benzinga.com IDEAYA Biosciences Q1 EPS $(1.11) Misses $(0.98) Estimate, Sales $6.560M Beat $5.008M Estimate IDEAYA Biosciences (NASDAQ:IDYA) reported quarterly losses of $(1.11) per share which missed the analyst consensus estimate of $(0.98) by 13.27 percent. This is a 35.37 percent decrease over losses…
- benzinga.com IDEAYA Biosciences Reveals Late-Breaking Abstract Oral Presentation At ASCO 2026 To Provide Complete Data from Phase 2/3 Registrational Trial Of Darovasertib In Combination With Crizotinib In 1L HLA*A2-Negative Metastatic Uveal Melanoma - IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a leading precision medicine oncology company, today announced they have been selected for a late-breaking abstract (LBA) oral presentation to provide the…
- benzinga.com Goldman Sachs Maintains Neutral on IDEAYA Biosciences, Raises Price Target to $35 Goldman Sachs analyst Corinne Jenkins maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Neutral and raises the price target from $31 to $35.
- benzinga.com Wells Fargo Maintains Overweight on IDEAYA Biosciences, Raises Price Target to $48 Wells Fargo analyst Eva Fortea Verdejo maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Overweight and raises the price target from $44 to $48.
- benzinga.com RBC Capital Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $53 RBC Capital analyst Leonid Timashev maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and raises the price target from $49 to $53.
- benzinga.com Wedbush Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $58 Wedbush analyst Robert Driscoll maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and raises the price target from $52 to $58.
- benzinga.com Guggenheim Maintains Buy on IDEAYA Biosciences, Raises Price Target to $54 Guggenheim analyst Paul Jeng maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and raises the price target from $50 to $54.
benzinga.com Leggett & Platt, Allogene Therapeutics, Revolution Medicines And Other Big Stocks Moving Higher On Monday U.S. stocks were mixed on Monday, with the Dow Jones falling over 200 points. Leggett & Platt rose on news of being acquired by Somnigroup.
benzinga.com IDEAYA Eye Cancer Trial Data Beats Standard Therapy, Stock Soars IDEAYA shares rise after darovasertib trial shows progression-free survival benefit in uveal melanoma; NDA filing planned for 2026.- benzinga.com Market-Moving News for April 13th IMA: 41% | ImageneBio Raises $30M Via Private Institutional Placement To Fund Hair Loss And Skin Disease Treatments IDYA: 37% | IDEAYA Biosciences and Servier's Topline Data From Phase 2/3 OptimUM-02…
- benzinga.com IDEAYA Biosciences and Servier's Topline Data From Phase 2/3 OptimUM-02 Trial Of Darovasertib Plus Crizotinib In HLA-A*02:01-Negative Metastatic Uveal Melanoma Met Primary Endpoint Trial met the primary endpoint showing statistically significant improvement in median PFS by BICR, with 6.9 months for the darovasertib combination versus 3.1 months for ICT (HR: 0.42; 95% CI: 0.30,…
benzinga.com Stock Market Today: Dow Futures Fall As Trump Announces Strait Of Hormuz Blockade—Goldman Sachs, Fastenal In Focus (UPDATED) Editor’s note: The future prices of benchmark tracking ETFs and pre-market prices of stocks have been updated. U.S. stock futures declined on Monday following Friday's mixed close. Futures of major…
benzinga.com Why IDEAYA Biosciences Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket IDEAYA Biosciences shares (NASDAQ: IDYA) jumped 18% in pre-market trading after announcing topline results from ongoing Phase 2/3 trial.
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session - benzinga.com IDEAYA And Servier To Release Topline Results From Phase 2/3 OptimUM-02 Trial In Metastatic Uveal Melanoma On April 13, 2026 IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company, today announced plans to issue a joint IDEAYA and Servier pre-market press release and host a conference call and…
- benzinga.com IDEAYA Biosciences Enrolls First Patient In Phase 1 Dose Escalation Trial Of IDE574 For Multiple Solid Tumors Potential first-in-class and selective equipotent dual inhibitor of KAT6/7 with single-digit to low teens nano-molar cellular potency in target engagement assays against KAT6 and KAT7, and…
- benzinga.com Wedbush Reiterates Outperform on IDEAYA Biosciences, Maintains $52 Price Target Wedbush analyst Robert Driscoll reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and maintains $52 price target.